Press ReleaseView printer-friendly version Back
Fibrocell to Present at 21st Annual BIO CEO & Investor Conference
A live webcast of Fibrocell’s presentation will be available under the Investors section of the Company’s website at www.fibrocell.com/investors/events and a replay will be available for 30 days following the event.
Fibrocell is an autologous cell and gene therapy company translating personalized biologics into medical breakthroughs for diseases affecting the skin and connective tissue. Fibrocell's most advanced product candidate, FCX-007, is the subject of a Phase 1/2 clinical trial for the treatment of RDEB. Fibrocell is also developing FCX-013, the Company's clinical stage candidate for the treatment of moderate to severe localized scleroderma. Fibrocell's gene therapy portfolio is being developed in collaboration with
Fibrocell®, the Fibrocell logo, and
Investor & Media Relations Contact: